QUESTCOR PHARMACEUTICALS INC - FORM 8-K - EX-99.2 - APRIL 2011 INVESTOR PRESENTATION

Attached files

file	filename
8-K - FORM 8-K - QUESTCOR PHARMACEUTICALS INC	d8k.htm
EX-99.1 - PRESS RELEASE - QUESTCOR PHARMACEUTICALS INC	dex991.htm

Exhibit 99.2

NASDAQ:

QCOR

NASDAQ:

QCOR

April 2011

Safe Harbor Statement

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been

made pursuant to the Private Securities Litigation Reform Act of

1995. These statements relate to future events or our future financial

performance. In some cases, you can identify forward-looking statements by terminology such as “believes,”

“continue,”

“could,”

“estimates,”

“expects,”

“growth,”

“may,”

“plans,”

“potential,”

“should,”

“substantial”

or “will”

or the negative of such terms and other

comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could

cause or contribute to such differences include, but are not limited to, the following: Our reliance on Acthar for substantially

all of our

net sales and profits; The complex nature of our manufacturing process and the potential for supply disruptions or other business

disruptions; The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;

Our ability to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop

other

therapeutic uses for Acthar; Research and development risks, including risks associated with Questcor's preliminary work in the area of

nephrotic syndrome and our reliance on third-parties to conduct research and development and the ability of research and

development to generate successful results; Regulatory changes or other policy actions by governmental authorities and other third

parties as recently adopted U.S. healthcare reform legislation is implemented; Our ability to receive high reimbursement levels from

third party payers; An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government

entities; Our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients and the

impact that unforeseen invoicing of historical Medicaid sales may have upon our results; Our ability to operate within an industry that

is highly regulated at both the Federal and state level; Our ability to effectively manage our growth and our reliance on key personnel;

The impact to our business caused by economic conditions; Our ability to protect our proprietary rights; Our ability to maintain

effective controls over financial reporting; The risk of product

liability lawsuits; Unforeseen business interruptions; Volatility in

Questcor's monthly and quarterly Acthar shipments and end-user demand, as well as volatility in our stock price; and Other

risks

discussed

Questcor's

annual

report

Form

10-K

for

the

year

ended

December

31,

2010

and

other

documents

filed

with

the

Securities and Exchange Commission.

The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and

future financial performance.